Prospective Grant of Exclusive License: Treatment of Proliferative Disorders Using an Unexpected mTOR Kinase Inhibitor

Zusammenfassung

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an exclusive license to practice the invention embodied in PCT patent application PCT/US2004/041265 filed December 9, 2004, entitled: "Methods for Suppressing an Immune Response or Treating a Proliferative Disorder" [HHS Reference Number: E-259-2003/0-PCT-02], to Emiliem, Inc., a Delaware Corporation, having a place of business in Emeryville, California. The field of use may be limited to the use of 2-(4-piperazinyl) substituted 4H-1-benzopyran-4-one compounds, including 2-(4-piperazinyl)-8-phenyl-4H-1-benzopyran-4-one (LY303511), for the treatment of cancer and/or other proliferative disorders not currently licensed, excluding the treatment and prevention of stenosis and restenosis. The United States of America is an assignee of the patent rights in these inventions.